Future strategies for the treatment of diastolic heart failure.
It is estimated that 30% to 50% of heart failure patients have preserved systolic left ventricular (LV) function, often referred to as diastolic heart failure (DHF). Mortality is high in this patient population, and morbidity and rate of hospitalization are similar to those of patients with systolic heart failure. The management of patients with diastolic heart failure is essentially empirical, limited, and disappointing. New drugs, devices, and gene therapy based treatment options are currently under investigation. In this review, future strategies for the treatment of diastolic heart failure are discussed.
Feld
Yair
Y
GeneGrafts Limited, Haifa, Israel. feld@genegrafts.com
Dubi
Shay
S
Reisner
Yotam
Y
Schwammenthal
Ehud
E
Elami
Amir
A
D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D003971:Diastole; D015316:Genetic Therapy / Q000379:methods*; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006353:Heart-Assist Devices; D006801:Humans; D009200:Myocardial Contraction / Q000502:physiology*; D016896:Treatment Outcome
D002317:Cardiovascular Agents